Skip to main content

Matinas BioPharma Holdings, Inc.

corporate_fare Company Profile

Matinas BioPharma Holdings, Inc.

MTNB·NYSE·Life Sciences·CIK 0001582554

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on delivering therapies using its lipid nanocrystal ("LNC") platform delivery technology (the "LNC Platform"). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug that, through LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. Following the successful EnACT Phase 2 trial in the treatment of cryptococcal meningitis, MAT2203 is positioned for a single Phase 3 registration trial (the "ORALTO trial") in support of a New Drug Application ("NDA") for the treatment of invasive aspergillosis in patients with limited treatment options. The company had also been seeking to develop an internal pipeline of products utilizing the LNC Platform to encapsulate small molecules and small oligonucleotides and facilitate targeted and extrahepatic delivery to desired cells and tissues without toxicity, with a focus on small molecule oncology applications and the formulation and delivery of small oligonucleotides with a primary therapeutic focus on inflammation. Following an 80% reduction in workforce implemented in late October 2024, Matinas implemented a cost-cutting strategy and paused further clinical development of MAT2203 while continuing to engage with prospective partners for the product with the goal of consummating a licensing, sale or other similar transaction as soon as possible to advance the development of MAT2203 into Phase 3. The company continues to engage with the United States Food and Drug Administration ("FDA") to keep the MAT2203 Investigational New Drug Application ("IND") active, is actively maintaining and prosecuting intellectual property relating to MAT2203 and the LNC Platform generally, and is maintaining all obligations under its license agreement with Rutgers University. It also continues to support patients in its Expanded/Compassionate Use Access Program with the assistance of outside medical clinician consultants.

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for MTNB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 9/10. Recent SEC coverage for MTNB spans 10-Q.

Recent high-impact activity:

  • Matinas 10-Q: Going-Concern Doubt With $1.9M Cash as GH Power Merger and Azurity Sale Pending

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$10.35M
Diluted EPS
-$2.00
Op. Cash Flow
-$7.01M
Operating Income
-$6.96M
Cash & Equivalents
$4M
Debt / Equity
0.00×
Shares Outstanding
6.41M sh
Source: 10-K · filed 2026-03-31 · accession 0001493152-26-014132

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 35,540 shares in MTNB as of the October 30, 2026 settlement, a 28.1% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 76.2% of MTNB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)35,540 shares as of October 30, 2026
Change vs prior period▼ 28.1%
Days to cover1.00 at avg daily volume of 54,667
Daily short volume (FINRA facilities)76.2% of 25,083 shares on November 20, 2026
5-day average short volume56.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.7694 -3.81% today
52-week range · as of 2026-11-16 $0.7694 – $18.75
Market cap
$890.71K
Volume
37.1K (0.7× avg)
3-mo avg 55.3K
Live data · 2026-11-22 12:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MTNB - Latest Insights

MTNB
Nov 16, 2026, 5:14 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.927
Real-time Price: $0.7694 info
Change: -$0.1576 (-17%) info
Market Cap: $890.711K info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets